Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaloacetate for cognitive complaints in breast cancer survivors
NCT04290897Phase 2Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Sep 2021
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of oxaloacetate in cancer-related cognitive impairment (CRCI), sponsored by UCLA Jonsson Comprehensive Cancer Center. Started Sep 2021; status: completed.
02
Drugs
oxaloacetate
03
Conditions
cancer-related cognitive impairment (CRCI)
Beyond the preview
Go deeper on NCT04290897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04290897.